Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
How dying tumor cells get noticed: Besides killing tumor cells directly, some chemotherapies, such as anthracyclines, also activate the immune system to kill tumors. Vacchelli et al. discovered that in mice, anthracycline-induced antitumor immunity requires immune cells to express the protein formyl peptide receptor 1 (FPR1). Dendritic cells (DCs) near tumors expressed especially high amounts of FPR1. DCs normally capture fragments of dying tumor cells and use them to activate nearby T cells to kill tumors, but DCs lacking FPR1 failed to do this effectively. Individuals with breast or colon cancer expressing a variant of FPR1 and treated with anthracyclines showed poor metastasis-free and overall survival. Thus, FPR1 may affect anti-tumor immunity in people, too. Science , this issue p. 972
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This confirmed that Fpr1 deficient immune cells interacted much less with dying cancer cells treated with anthracyclines than immune cells expressing functional Fpr1 (Fig. 3B), explaining why Fpr1 deficiency leads to defective anticancer immune response and less efficient chemotherapy.”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Recently, Vacchelli et al. identified a loss of-function mutation in the allele of the gene coding for formyl peptide receptor 1 (Fpr1) that correlated with poor survival in breast and colorectal cancer patients receiving adjuvant chemotherapy[62].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [62]
In the citing paper
“Extracellular ANXA1 reportedly acts as a DAMP and supports the activation of adaptive immune responses by engaging formyl peptide receptor 1 (FPR1) on DCs [876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
In the citing paper
“In line with these observations, RCD is not perceived as immunogenic when cancer cells are depleted of HMGB1 or ANXA1, as well as when the host lacks TLR4 or FPR1 [870, 876].”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [876]
Citations
Cites
Fiji: an open-source platform for biological-image analysis
Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid, B., et al. (2012) · Nature Methods · doi:10.1038/nmeth.2019 · Cited by 66,890
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Maere, S., Heymans, K., & Kuiper, M. (2005) · Bioinformatics · doi:10.1093/bioinformatics/bti551 · Cited by 4,155
Immunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
Self-citationApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Self-citationMore powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
Ghiringhelli, F., Apetoh, L., Tesniere, A., Aymeric, L., Ma, Y., Ortiz, C., Vermaelen, K., Panaretakis, T., Mignot, G., Ullrich, E., et al. (2009) · Nature Medicine · doi:10.1038/nm.2028 · Cited by 1,898
Self-citationDenkert, C., Loibl, S., Noske, A., Roller, M., Müller, B. M., Komor, M., Budczies, J., Darb-Esfahani, S., Kronenwett, R., Hanusch, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7370 · Cited by 1,762
Cited by
Items 401–452 of 452
Chen, B., Jia, Y., Meng, L., & Hu, N. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1764908 · Cited by 1
“Preclinical studies have demonstrated the synergistic effect of nivolumab and ipilimumab in mouse models (32).”
Wang, H., Yu, Y., Zhou, W., Miao, B., Zhang, Y., Zhu, J., Lin, Z., Han, J., Xu, X., Zhang, F., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04359-5 · Cited by 3
“Prior studies identified ICD activation as the critical upstream event driving CD8 ⁺ T cell infiltration and the conversion of cold into hot tumors [54, 55].”
Onimus, A., Celias, D. P., Chang, S., Davis, J., Mandula, J. K., Li, J., Gardner, A., Hänggi, K., Osunmakinde, O., Soliman, H., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102788 · Cited by 1
Jin, Z., Zhang, X., Zhang, H., Qin, S., Zhang, S., Zhang, S., Xia, L., Li, P., Xu, W., Liu, P., et al. (2026) · Science China Life Sciences · doi:10.1007/s11427-026-3427-0 · Cited by 1
“The FPR1-ANXA1 axis plays a crucial role in orchestrating chemotherapy-induced anti-tumor immunity, including type I IFN responses, tumor antigen uptake and presentation by DCs, and cytotoxic T cell response (Vacchelli et al., 2015).”
Self-citationCell Death: Many Causes and Many Effects
Cokkinos, D. V. (2019) · Springer eBooks · doi:10.1007/978-3-319-98186-4_7 · Cited by 1
Interdisciplinary research in cancer and immunity employing biophysical approaches
Mattei, F., & Jolly, M. K. (2023) · iScience · doi:10.1016/j.isci.2023.106507 · Cited by 1
Self-citationKhamarudin, F., Muhamad, M., Khan, J., Ibahim, M. J., Zain, W. N. I. W. M., Aziz, M. A., Ridzuan, N. R. A., & Rahim, S. A. (2023) · Malaysian Applied Biology · doi:10.55230/mabjournal.v52i6.2413 · Cited by 1
“…agents, have been shown to induce immunomodulatory effects on a variety of cancer cells by increasing calreticulin (CRT) expression on the cell surface, followed by the release of high mobility group box 1 (HMGB1), ATP, annexin A1, and type I interferon from cancer cells (Vacchelli et al ., 2015).”
BackgroundOrgan-on-chip-based disease models
Fernández‐Costa, J. M., Chiara, F. D., & Ramón‐Azcón, J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15384-6.00005-7 · Cited by 1
Harnessing Natural Products of Marine Origin for Induction of Immunogenic Cell Death
Raja, M. R. K., Chen, K., & Raja, M. R. K. (2021) · Clinical Oncology and Research · doi:10.31487/j.cor.2021.08.06
Molecular Mechanisms of Immunogenic Cell Death
Musella, M., Manic, G., Vitale, I., & Sistigu, A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.12294-0
Self-citationMolecular Mechanisms of Tumor Dendritic Cell Dysfunction in Cancer
Tang, M. (2016) · TSpace (University of Toronto)
Medrano, R. F. V. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-06042018-122815
What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study
Battaglin, F., & Lenz, H. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy217 · Cited by 1
Zucali, P. A. (2019) · Springer eBooks · doi:10.1007/978-3-030-31113-1_1
Investigation of Bacterial Interactions Using Lab on Chips
Nichele, L., Ninno, A. D., Gerardino, A., Bertani, F. R., Visaggio, D., Lucidi, M., Visca, P., Businaro, L., & Cincotti, G. (2020) · International Conference on Transparent Optical Networks · doi:10.1109/icton51198.2020.9203049
“Microfluidic approaches can be a useful tool to in vitro study these interactions [4, 5], and microfabrication generates controlled spaces where it is possible to simulate some physiological conditions for bacterial growth [6].”
BackgroundSelf-citationAdvances in antitumor chemotherapy effects on immune function
Huang, D. J., & Liang, X. (2020) · Scientia Sinica Vitae · doi:10.1360/ssv-2020-0020
Jiang, X., Gao, Y., Zhang, N., Yuan, C., Luo, Y., Sun, W., Zhang, J., Ren, J., Gong, Y. Q., & Xie, C. (2020) · doi:10.21203/rs.3.rs-16969/v1
N'guyen, M. J., Ninno, A. D., Mencattini, A., Mermet‐Meillon, F., Fornabaio, G., Evans, S. S., Cossutta, M., Khira, Y., Sirven, P., Pelon, F., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3188441
Self-citationBao, L., Sun, K., & Zhang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-961645/v1
Kirtek, T. J., Hamdan, H., Arnam, J. S. V., Park, S. I., Kovach, A. E., Pillai, V., & Weinberg, O. K. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4115600
Bibliometric and visualization analysis of immunogenic cell death from 2012 to 2022 (Preprint)Preprint
Zhang, C., Tan, Y., Wang, J., Huang, J., Chen, T., Zhang, S., Liu, Z., Zou, C., & Qin, B. (2023) · doi:10.2196/preprints.47045
xie, G., Xu, Y., Bao, L., He, T., Ren, X., Ji, J., Meng, X., Zhao, B., & Wang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2764971/v1
Merging On-chip and In-silico Modelling for Improved Understanding of Complex Biological Systems
Bertani, F. R., Bretti, G., Businaro, L., Ninno, A. D., Gerardino, A., & Natalini, R. (2023) · SEMA SIMAI Springer series · doi:10.1007/978-3-031-35715-2_2
Self-citationCo-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
Manduca, N., Maccafeo, E., Ninno, A. D., Sistigu, A., & Musella, M. (2024) · Journal of Visualized Experiments · doi:10.3791/66729
Self-citationNoto, F., Ninno, A. D., Falchi, M., Businaro, L., Schiavoni, G., & Mattei, F. (2025) · Methods in cell biology · doi:10.1016/bs.mcb.2025.01.005
Self-citationClavero, A. L., Kopsida, M., Arendt, N., Lennernäs, H., Sjöblom, M., & Heindryckx, F. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.14.643356
Kinetic Assessment of HMGB1 Exodus by Automated Live Cell Imaging
Leduc, M., Forveille, S., Kroemer, G., Sauvat, A., & Kepp, O. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4558-1_10
Self-citationPetrazzuolo, A., Carbonnier, V., Palma, F. D. E. D., Pérez-Lanzón, M., Vergé, V., Quivoron, C., Lamant, L., Brugières, L., Rigaud, C., Ducassou, S., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07410-5
“Our group demonstrated that the loss-of-function variant rs867228 of FPR1 is associated with precocious onset of breast, colorectal, esophageal and head & neck carcinomas [18].”
Self-citationBai, Y., Hu, Y., Li, L., Qian, H., Wang, X., Ma, Y., Lu, F., Qin, K., Wang, J., & 叶俏波 (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117870
Self-citation2D and 3D cellular screening models and AI guided analysis
Kepp, O., & Kroemer, G. (2026) · Methods in cell biology · doi:10.1016/s0091-679x(26)00104-4
Self-citationCrizotinib-Induced Immunogenic Cell Death in Non-Small Cell Lung Cancer
Liu, P. (2018) · theses.fr (ABES) · doi:10.70675/ed550df1z9febz41d6z9846z294a6695b865
Üner, G., Ulker, C., Ballar, P., & Bedіr, E. (2026) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2026.03.002
Inhibition of Transcription by Dactinomycin Reveals a New Characteristic of Immunogenic Cell Stress
Humeau, J. (2019) · theses.fr (ABES) · doi:10.70675/e42505daza57fz459az9dc5z1ef744d25b38
Bénéfice des modulateurs métaboliques en combinaison aux chimio-immunothérapies anticancéreuses
Lévesque, S. (2019) · theses.fr (ABES) · doi:10.70675/db466876zeec8z4537za0e0zc0f1fa485cea
Annexine A1 : dissémination et microenvironnement tumoral
Delorme, S. (2020) · theses.fr (ABES) · doi:10.70675/4e6e1c64z0a30z47bczb53cz2e00956cfcd8
Modeling Hormone Receptor Positive Breast Cancer in Immunocompetent Mice
Pérez-Lanzón, M. (2021) · theses.fr (ABES) · doi:10.70675/8d0cd788z71c4z4627z898ezbb2b6500fa17
Rôle de TRIM33 dans l'immunothérapie anti-tumorale radio-induite
Assouvie, A. (2021) · theses.fr (ABES) · doi:10.70675/bc108f50z5815z424dz84c9z480836dbb865
Modulation of tumor immunogenicity with AMPK activation in acute myeloid leukemia
Mondésir, J. (2021) · theses.fr (ABES) · doi:10.70675/2693bda5ze768z4bf0z857bze1eb8ccccc80
Naour, J. L. (2022) · theses.fr (ABES) · doi:10.70675/ad2bd68az83cdz4738zb39fz6a66ef3080d3
Ruggiu, M. (2023) · theses.fr (ABES) · doi:10.70675/de84e089z4e46z475dz8d12z25950ab6f427
Restoring dendritic cell migration: a gut reaction to boost vaccine efficacy in aging
Zhao, L., Kepp, O., Kroemer, G., & Liu, P. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2657070 · Cited by 1
Self-citationFRα-targeted PDT in ovarian cancer: beyond cytotoxicity, an immunomodulatory therapy
Ali, N. H., Stoup, N., Moralès, O., Kerbage, Y., & Delhem, N. (2026) · Cell Signaling · doi:10.46439/signaling.4.098
Teiama, M. S. A., Gohar, A., Amr, M., El‐Shinawi, M., & Elkhatib, W. F. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00534-0
“Recent studies have also shown that DCs lacking or expressing a variant of Formyl Peptide Receptor 1 (FRP1) exhibit failure of T-cell activation and a poor immune response in tumor types such as colon and breast cancer [77].”
FPR1-Driven Neutrophil-Endothelial Cell Axis Promotes Angiogenesis in PAOD
Li, F., Zhao, P., Wei, T., Zha, Y., Zhao, X., Woodman, O. L., Chen, Y., Zhou, X., & Qin, C. X. (2026) · Circulation Research · doi:10.1161/circresaha.126.328454
SRSF3 confers cuproptosis resistance in oral cancer by suppressing FDX1 expression
Zhang, Z., Yan, L., Guo, J., & Jia, R. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112891
Disinhibiting dendritic cell-natural killer cell cooperation against metastasis
Kepp, O., & Kroemer, G. (2026) · Immunity & Inflammation · doi:10.1007/s44466-026-00060-2
“These observations have generally been interpreted through defective sensing of ANXA1 emitted by dying or stressed cancer cells [5].”
Self-citationPhysiCell Validation of a Discrete-in-Continuous Mathematical Model for Cancer-on-Chip Experiments
Gennaro, M. D., Braun, E. C., & Bretti, G. (2026) · Lecture notes in computer science · doi:10.1007/978-3-032-41794-7_9
Combination of antibody–drug conjugates with immunotherapy: a new paradigm in cancer treatment
Lai, Y., Qin, R., & 刘寨东 (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1945452
Mechanisms and pharmacological modulation of photodynamic therapy-induced cell death
de Klerk, D. J., Tian, J., Liu, G., Korbelik, M., Kessel, D., Chovanec, M., Khaled, Y. S., van Eijck, C. H. J., Wu, L., & Heger, M. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100166
Metadata
- Authors
- Vacchelli, E., Ma, Y., Baracco, E. E., Sistigu, A., Enot, D. P., Pietrocola, F., Yang, H., Adjemian, S., Chaba, K., Semeraro, M., Signore, M., De Ninno, A., Lucarini, V., Peschiaroli, F., Businaro, L., Gerardino, A., Manic, G., Ulas, T., Günther, P., Schultze, J. L., Kepp, O., Stoll, G., Lefebvre, C., Mulot, C., Castoldi, F., Rusakiewicz, S., Ladoire, S., Apetoh, L., Bravo-San Pedro, J. M., Lucattelli, M., Delarasse, C., Boige, V., Ducreux, M., Delaloge, S., Borg, C., André, F., Schiavoni, G., Vitale, I., Laurent-Puig, P., Mattei, F., Zitvogel, L., & Kroemer, G.
- Affiliations
- Inserm (FR)
- Instituto Nazionale Tumori Regina Elena (IT)
- Gustave Roussy Cancer Campus, Villejuif, France.
- Istituto Superiore di Sanità (IT)
- Italian National Research Council, Institute for Photonics and Nanotechnology, Rome, Italy.
- National Research Council (IT)
- University of Bonn (DE)
- Centre Georges François Leclerc (FR)
- Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
- University of Siena (IT)
- Centre National de la Recherche Scientifique (FR)
- Université Paris-Saclay (FR)
- University of Rome Tor Vergata (IT)
- Université Paris Sorbonne Cité, UMRS 775, INSERM, Paris, France.
- Karolinska University Hospital (SE)
- Corresponding author
- Zitvogel, Laurence
- ORCID
- Vacchelli, Erika
- Ma, Yuting
- Sistigu, Antonella
- Pietrocola, Federico
- Yang, Heng
- Adjemian, Sandy
- Signore, Michele
- Businaro, Luca
- Gerardino, Annamaria
- Manic, Gwenola
- Ulas, Thomas
- Günther, Patrick
- Schultze, Joachim L.
- Kepp, Oliver
- Stoll, Gautier
- Mulot, Claire
- Castoldi, Francesca
- Rusakiewicz, Sylvie
- Ladoire, Sylvain
- Lucattelli, Monica
- Delarasse, Cécile
- Boige, Valérie
- Ducreux, Michel
- Delaloge, Suzette
- Borg, Christophe
- André, Fabrice
- Schiavoni, Giovanna
- Vitale, Ilio
- Mattei, Fabrizio
- Zitvogel, Laurence
- Kroemer, Guido
- Venue
- Science
- Published
- 2015-11-20
- Volume
- 350
- Issue
- 6263
- Pages
- 972-978
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1911271782
- Cited by
- 452
- References
- 40
- Citations by year
- 2026: 25 · 2025: 25 · 2024: 29 · 2023: 51 · 2022: 38 · 2021: 50 · 2020: 58 · 2019: 47 · 2018: 45 · 2017: 40 · 2016: 42 · 2015: 1
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-10-LABX-0015, ANR-10-INBS-0001, ANR-10-IBHU-0001)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- FPR1, anthracycline chemotherapy, antitumor immunity, annexin A1, cancer cell death, T cell immunity, breast cancer, colorectal cancer, adjuvant chemotherapy, loss-of-function alleles, microfluidics, metastasis-free survival
- MeSH terms
- Alleles, Animals, Breast Neoplasms, Dendritic Cells, Female, Humans, Immunity, Innate, Leukocytes, Neoplasms, T-Lymphocytes, Colorectal Neoplasms, Chemotherapy, Adjuvant, Annexin A1, Anthracyclines, Polymorphism, Single Nucleotide, Receptors, Formyl Peptide, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.